TRIVEX Study Presented at Charing Cross Symposium

LEXINGTON, Mass. – April 8, 2009 -- InaVein, LLC announced today that positive clinical data on its TRIVEX System used for the removal of extensive varicose veins was presented at the Charing Cross Symposium (Imperial College, London, UK) on April 7th by Jennifer A. Heller, MD, FACS. The annual Charing Cross Symposium is Europe’s longest running and leading vascular surgery symposium with > 2,000 clinicians attending from 71 countries. Dr. Heller, Assistant Professor of Surgery and, Director and Chief of the Johns Hopkins Vein Center, Baltimore, MD USA, presented her data using the TRIVEX System on 114 limbs in 93 patients. All procedures were completed successfully with no intraoperative complications. According to Dr. Heller: “This experience demonstrates successful performance of powered phlebectomy in an outpatient setting with excellent results”.

About InaVein
InaVein, LLC is a privately held company engaged in the development, manufacture, marketing and commercialization of unique medical devices for the treatment of vein disease. The company’s flagship product, The TRIVEX™ System, is the first technology to provide surgeons with a minimally invasive technique to remove varicose veins safely and efficiently under direct vision. Since 2003, thousands of patients worldwide have been successfully treated using The TRIVEX System to completely remove their varicose veins. In addition, the company is developing other vascular products to assist clinicians in treating the full spectrum of conditions caused by peripheral venous disease.

For more information please contact:
InaVein
Michael McCartin
Vice President-Marketing and Sales
617.245.1965 ext. 1107